Investment Overview
Strategy Description
R3 is led by a $50m anchor commitment from a top decile institutional investor, and has soft-circled commitments exceeding $100m for its regenerative medicine incubation studio in Boston. R3 is structured to develop assets internally & make direct investments, to maintain flexibility in supporting our portfolio and achieving our investment goals. R3 will leverage its lead investor's proven incubation model, whose prior life science portfolios have returned 6x MOC in aggregate across the past two decades (from Vivo Ventures, Kleiner Perkins, and Panacea I portfolios). R3’s team also includes the executive and scientific leadership of the Harvard Stem Cell Institute, which wrote the first check into the lab that created Moderna. Another 5 unicorns have emerged from HSCI in the past decade.
We are confident in our ability to create category-defining medicines of the future, and generate exceptional value for our investors, scientists, patients & the world. We ask you to join us in this effort, and appreciate your interest. Expected initial closing in Q3 2021, and due to a limited overallotment, interested parties are asked to move quickly.
